Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

How Is Chembio (CEMI) Stock Skyrocketing 95% in Premarket Session?

By ST Staff
Published On July 21, 2021 1:28 PM UTC
How Is Chembio (CEMI) Stock Skyrocketing 95% in Premarket Session?

Shares of leading point-of-care diagnostic company focused on infectious diseases Chembio Diagnostics Inc. (CEMI) were trading up 94.66% at $4.01 in premarket trading on Wednesday. Chembio stock decreased -16.26% to end last trading session at $2.06. CEMI stock traded 1.39 million shares on the day, above its average daily trading volume of 0.48 million shares for the previous 50 days.

In the last five days, CEMI stock share prices have retreated by -20.77; however, over the last month, they have fallen by -32.01%. Over the last three months, CEMI stock price plummeted by 43.25%, and so far this year, it has lost -56.63 percent. After receiving a multimillion-dollar order, CEMI stock has gained traction.

Who placed the order with CEMI?

Chembio is one of North America’s leading point-of-care diagnostics companies that specializes in detecting and diagnosing infectious diseases including COVID-19, respiratory disease, and insect-bite diseases. With CEMI’s vast scientific expertise, its novel DPP technology has a wide range of application beyond infectious diseases. Healthcare organizations, physician offices, clinical labs, government agencies, and consumers receive CEMI’s products directly and through distributors globally.

Yesterday, Chembio announced that it had received a 28.3 million dollar purchase order from Bio-Manguinhos.

  • Chembio’s DPP SARS-CoV-2 Antigen tests for delivery during 2021 were ordered by Bio-Manguinhos to support an urgent need of the Brazilian Ministry of Health to fight the COVID-19 pandemic.
  • The DPP SARS-CoV-2 Antigen test, which uses a nasal swab to detect the antigen, uses a minimally invasive technique to detect COVID-19 infection in only 20 minutes.
  • Chembio’s supply chain, staffing, liquidity, and other matters outside Chembio’s control may prevent CEMI from delivering all the tests on the purchase order.
  • A small drop of blood from the fingertip or alternative samples allows CEMI to provide high-quality, rapid testing results in 15 to 20 minutes.
  • A single patient sample can produce up to eight test results using CEMI’s DPP platform, providing more clinical value than other rapid tests.
  • With CEMI’s highly portable, battery-powered DPP Micro Reader, users can easily and accurately perform certain types of decentralized testing where real-time results can be obtained while patients are still on the spot.
  • Objectivity produces results that reduce the potential for human error that can occur in many rapid tests requiring visual interpretations.

A worthwhile investment by CEMI:

Chembio (CEMI) significant expansion of customer relations with Bio-Manguinhos has been encouraging as it addresses COVID-19 testing needs. As a result of this purchase order, CEMI is set to ramp up its production of the DPP SARS-CoV-2 Antigen test, justifying the investments it made earlier in the year.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph